Do ED Medications Protect the Heart? What the Evidence Actually Shows

শেষ আপডেট: আগস্ট 21, 2026

• ওয়ার্ডপ্রেস
• লিঙ্কডইন
• মেইল

Here is a piece of medical history most people do not know: sildenafil was never meant to be an erection drug.

It was developed as a treatment for angina — chest pain from poor blood supply to the heart. The effect on erections turned up as an unexpected finding during trials, and the rest is one of the most famous accidents in pharmaceutical history. The heart indication was quietly shelved.

Which makes what has happened since rather interesting. Over the past two decades, researchers have circled back to the original question, and a considerable body of evidence now suggests these medications may do something genuinely useful for the cardiovascular system.

I want to walk through that evidence carefully, because this is a topic where enthusiasm runs ahead of proof — and where the wrong conclusion could put someone in real danger. So let me state the honest summary before anything else: the findings are intriguing and consistent, but they are not proof, and nobody should be taking these medications for their heart.

Why a Sex Medication Would Affect the Heart at All

The connection is less strange than it sounds once you know what these drugs actually do.

Sildenafil, tadalafil, and vardenafil belong to a family called PDE5 inhibitors. They work on a signalling chemical the body uses to relax blood vessels. Normally an enzyme breaks that chemical down; these drugs block the enzyme, so the signal lasts longer, vessels relax more, and blood flows more freely.

The crucial point is that this enzyme is not confined to the penis. It sits throughout the body’s blood vessels — and, notably, inside heart muscle that has become thickened and strained. That is why a drug developed for one purpose keeps turning up in unrelated cardiovascular research, and why these same medications are already formally approved for a serious lung-artery condition.

In laboratory and animal studies, boosting that signal in heart tissue appears to do several helpful things at once: it protects heart muscle cells from dying when blood supply is interrupted, reduces scarring, calms inflammation, and improves how well the lining of blood vessels functions. In one striking study, treatment did not just prevent thickening of the heart muscle in mice under strain — it partially reversed thickening that had already developed.

The laboratory story, in other words, is genuinely coherent. The difficulty is what happens when you move from mice to men.

What the Human Studies Found

Two categories of human evidence matter here, and they point in different directions.

The large population studies — consistently encouraging

Researchers have examined enormous groups of men who happened to be taking these medications for erectile dysfunction, then tracked what happened to their hearts over the following years.

A very large American analysis of men with erectile dysfunction and cardiovascular risk factors found that those taking PDE5 inhibitors had fewer major cardiac events, fewer hospital admissions for heart failure, fewer procedures to open blocked arteries, and lower overall death rates than men who were not.

A Swedish nationwide study looked at men who already had established coronary artery disease, and did something clever: instead of comparing them with men on no treatment, it compared them with men using a different erectile dysfunction treatment. That comparison matters, because both groups were men seeking help for the same problem — which strips away a lot of the difference in health-seeking behaviour. The men on PDE5 inhibitors still had lower rates of death, heart attack, heart failure, and artery procedures.

And across these studies one pattern keeps appearing that is hard to ignore: the more of the medication a man was taking, the larger the apparent benefit. A dose-response relationship like that is one of the classic signals that an association may be real rather than coincidental.

The controlled trials — decidedly mixed

When researchers have run proper randomised trials, giving the drug to some patients and a dummy tablet to others, results have been far less tidy.

Pooled analyses of many trials do suggest real structural benefits — thickened heart muscle became less thick, and pumping function improved modestly, particularly in patients who started with significant thickening. Vascular measurements also improved: blood pressure edged down and the lining of the arteries worked better.

But in heart failure the picture splits. In patients whose heart muscle pumps poorly, some studies showed improved exercise capacity and quality of life — mainly in those who also had raised pressure in the lung arteries — while others showed no benefit at all. In patients whose heart pumps normally but stiffens, a major trial found no improvement in exercise capacity, symptoms, or heart structure.

The lesson is that these drugs are not a general heart tonic. Where benefit appears, it appears in specific patients with specific problems.

Two Areas Genuinely Worth Watching

Diabetes. Men with type 2 diabetes have both a high rate of erectile dysfunction and a high rate of heart disease, for the same underlying reason: damaged blood vessels and chronic low-grade inflammation. A trial of daily tadalafil in people with type 2 diabetes and early changes in heart structure found improvements in how the heart muscle twists and contracts, along with better markers of kidney function and inflammation. Curiously, the heart-motion benefit appeared in men but not women — a sex difference nobody yet fully understands, and a reminder that most of this research has been done in men.

Chemotherapy protection. Certain chemotherapy drugs damage heart muscle, and that damage sometimes limits how much cancer treatment a patient can safely receive. In animal studies, PDE5 inhibitors protected the heart from this damage ছাড়া blunting the chemotherapy’s effect on the tumour. That combination is exactly what you would want, and it is now one of the most actively pursued questions in this field. It has not yet been established in patients.

Why This Is Not Proof — Three Honest Caveats

I would be doing readers a disservice if I presented the encouraging findings without the problems attached to them.

First, most of the reassuring evidence is observational. These studies watched what happened to men who were already taking the medication. They did not assign treatment randomly. That leaves room for the possibility that something other than the drug explains the difference.

Second, and specifically, there is the healthy-user problem. Consider what kind of man obtains and regularly uses an erectile dysfunction medication. He is engaged with his health. He sees a doctor. He is likely still sexually active, which itself tracks with better general health. He can afford the prescription. Every one of those traits independently predicts a healthier heart. Statistical adjustment helps, but it cannot fully remove a bias built into who receives the treatment in the first place.

Third, the trials that could settle it have not been done. Nobody has run a large randomised trial designed specifically to test whether these medications prevent heart attacks and deaths. Until someone does, this remains a promising hypothesis rather than an established fact. Medicine has been badly burned before by observational findings that evaporated under proper testing.

The Warning That Matters More Than Any of This

If you remember one thing from this article, make it this.

PDE5 inhibitors must never be combined with nitrate medications.

Nitrates are heart medicines — nitroglycerin tablets or sprays for chest pain, and related drugs such as isosorbide. Both nitrates and PDE5 inhibitors relax blood vessels through the same pathway. Taken together they can amplify each other and cause a catastrophic drop in blood pressure.

Current cardiology guidelines are specific about timing: after taking sildenafil or vardenafil, nitrates should be avoided for at least twenty-four hours, and after tadalafil — which lasts considerably longer in the body — for at least forty-eight hours.

Some recent studies examining men who were prescribed both have not found the increase in harm you might expect, which has generated some discussion. I would not read that as permission. The mechanism is real, the potential consequence is severe, and the sensible response to conflicting data on a dangerous interaction is caution, not relaxation.

This is precisely why nobody should obtain these medications informally. Your doctor needs to know your full medication list — and if you carry a nitrate spray for chest pain, that changes the conversation entirely.

The Connection That Is Already Proven

While the heart-protection question remains open, there is a related link between erections and the heart that is নয় in doubt, and it is arguably more important for the average man.

Erectile dysfunction is frequently an early warning sign of cardiovascular disease. The arteries supplying the penis are narrower than the coronary arteries, so the same disease process that eventually blocks a heart artery tends to show itself in erections first — often years before any chest pain appears. This is the focus of my own research work with the team at Baylor College of Medicine, examining how far in advance erectile dysfunction can flag cardiovascular risk.

The practical implication is considerable. New erectile dysfunction, particularly in a man under sixty, deserves a cardiovascular assessment — blood pressure, cholesterol, blood sugar, and a proper risk discussion — not just a prescription. The consultation you attend for one problem may be the one that catches the other in time.

শেষ কথা

The evidence that PDE5 inhibitors may protect the heart is real, mechanistically sensible, and consistent across large populations. It is also not proof, and it does not currently justify prescribing these medications to anyone for cardiovascular reasons.

What it does justify is reassurance. If you have erectile dysfunction alongside cardiovascular risk factors — and a great many men do — the evidence indicates these medications are safe for your heart in appropriate circumstances, with the absolute exception of nitrates. That matters, because fear of harming the heart still stops men from seeking treatment for a problem that is affecting their lives.

What it does নয় justify is anyone taking these tablets to protect their heart, and certainly not obtaining them without a prescription on that basis. If you want to protect your cardiovascular system, the interventions that are actually proven remain unglamorous and unchanged: control your blood pressure, manage your cholesterol and blood sugar, stop smoking, move your body, and sleep properly.

See how erectile dysfunction treatment is structured in practice, including the cardiovascular assessment that should accompany it, and how টেস্টোস্টেরন প্রতিস্থাপন থেরাপি fits into broader men’s health care.

If you have erectile difficulties — particularly alongside diabetes, high blood pressure, or a family history of heart disease — please have it assessed properly rather than self-treating. Dr. Soarawee Weerasopone offers specialist consultations in men’s health and sexual medicine at Bangkok Hospital Headquarters. পরামর্শ বুক করুন. Consultations are also available at Samitivej Sriracha Hospital, Chonburi — please call the department line on 088-022-1445. Bangkok Hospital Telemedicine is available for patients who cannot attend in person, including international patients — arrange it in advance by email to the Urology department at bhquro@bdms.co.th. A video consultation is a reasonable way to go through your symptoms and your current medication list, which matters here more than usual: whether you take a nitrate decides what can safely be prescribed. Examination and any testing are done in person, and Samitivej Sriracha is in-person only.

Frequently Asked Questions About ED Medications and Heart Health

Do ED medications such as sildenafil and tadalafil protect the heart?

Possibly, but this is not proven. Large observational studies have consistently found that men taking PDE5 inhibitors for erectile dysfunction experience fewer major cardiac events and lower death rates, with greater apparent benefit at higher use. Laboratory research supports a plausible mechanism. However, no large randomised trial has been designed to test whether these drugs actually prevent heart attacks, and the observational findings may be influenced by the fact that men who seek and use these medications tend to be healthier overall. No medical guideline currently recommends them for cardiovascular protection.

Are ED medications safe for men with heart disease?

For most men with stable cardiovascular disease, yes, when prescribed and monitored by a doctor. Extensive clinical experience has not shown an increase in cardiac events with these medications, including in men with coronary artery disease or heart failure. The critical exception is nitrate medication, which must never be combined with PDE5 inhibitors. Men with unstable cardiac symptoms, very low blood pressure, or recent cardiac events need individual assessment before starting treatment.

Why can’t PDE5 inhibitors be taken with nitrates?

Both nitrates and PDE5 inhibitors relax blood vessels through the same biological pathway, so combining them can amplify the effect and cause a dangerous fall in blood pressure. Nitrates include nitroglycerin tablets and sprays used for chest pain, as well as related drugs such as isosorbide. Guidelines advise avoiding nitrates for at least twenty-four hours after sildenafil or vardenafil, and at least forty-eight hours after tadalafil because it remains in the body longer. Anyone who carries a nitrate spray must tell their doctor before being prescribed an erectile dysfunction medication.

Was Viagra originally a heart medication?

Yes. Sildenafil was developed as a treatment for angina, the chest pain caused by inadequate blood supply to the heart. Its effect on erections was discovered unexpectedly during clinical trials, and that became its famous indication instead. The same class of medication was later approved for pulmonary arterial hypertension, a condition affecting the arteries of the lungs. Current research into cardiovascular protection is in a sense a return to the original question these drugs were designed to answer.

Is erectile dysfunction a warning sign of heart disease?

Yes, and this link is well established rather than speculative. The arteries supplying the penis are narrower than the coronary arteries, so the same disease process that narrows heart arteries often produces erectile symptoms first, sometimes years before any chest pain occurs. New erectile dysfunction, particularly in a man under sixty, warrants cardiovascular assessment including blood pressure, cholesterol, and blood sugar rather than a prescription alone.

তথ্যসূত্র

1. Kloner RA, Stanek E, Crowe CL, et al. Effect of phosphodiesterase type 5 inhibitors on major adverse cardiovascular events and overall mortality in a large nationwide cohort of men with erectile dysfunction and cardiovascular risk factors. J Sex Med. 2023;20(1):38–48. PubMed
2. Andersson DP, Landucci L, Lagerros YT, et al. Association of phosphodiesterase-5 inhibitors versus alprostadil with survival in men with coronary artery disease. J Am Coll Cardiol. 2021;77(12):1535–1550. PubMed
3. Hutchings DC, Anderson SG, Caldwell JL, Trafford AW. Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection? Heart. 2018;104(15):1244–1250. PubMed
4. Giannetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12:185. PubMed
5. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11(2):214–222. PubMed
6. Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA. 2013;309(12):1268–1277. PubMed
7. Pofi R, Giannetta E, Feola T, et al. Sex-specific effects of daily tadalafil on diabetic heart kinetics in RECOGITO, a randomized, double-blind, placebo-controlled trial. Sci Transl Med. 2022;14(649):eabl8834. PubMed
8. Das A, Durrant D, Salloum FN, Xi L, Kukreja RC. PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. Pharmacol Ther. 2015;147:12–21. PubMed
9. Schwartz BG, Levine LA, Comstock G, Stecher VJ, Kloner RA. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012;59(1):9–15. PubMed
10. Trolle Lagerros Y, Grotta A, Freyland S, Grannas D, Andersson DP. Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2024;83(3):417–426. PubMed
11. Zhang Y, Peng H, Xin S, et al. Associations between phosphodiesterase type 5 inhibitors and vascular function: a systematic review and meta-analysis of randomized controlled trials. Syst Rev. 2025. PubMed

মেডিকেল লেখা এবং পর্যালোচিত: Dr. Soarawee Weerasopone (Dr. Pom) — Board-Certified Urologist, Bangkok Hospital Headquarters.
Research Scholar & Clinical Observer, Scott Department of Urology, Baylor College of Medicine (USA) · Endourology Observership, Juntendo University (Japan) · Robotic Surgery Fellowship, Chang Gung Memorial Hospital (Taiwan)

দাবি পরিত্যাগ This content is written and reviewed by Dr. Soarawee Weerasopone, a board-certified urologist at Bangkok Hospital Headquarters. It is intended for educational purposes only and does not constitute medical advice. PDE5 inhibitors are not approved or recommended for cardiovascular protection, and should only be taken when prescribed by a qualified doctor who knows your full medical and medication history. Medical advice, diagnosis and prescriptions are not provided through personal messaging channels or social media. Always consult a qualified healthcare professional before starting any medical treatment.